About: Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection
Creator	Corti, Davide Pinna, Debora Seehusen, Frauke Hu, Yue Mestecky, Jiri Morone, Diego Ivanyi, Juraj Joshi, Sangeeta Volkin, David Jaconi, Stefano Acosta, Armando Bajoria, Sakshi Benigni, Fabio Grassi, Fabio Lombardo, Gloria Perruzza, Lisa Piantanida, Renato Pizzuto, Matteo Strati, Francesco Xiong, Jian Bio, Pizzuto Db, Volkin Os, Kumru Samuele, Matteo Sb, Joshi Selahattin Kumru, Ozan Xiong, Bajoria
Source	PMC
abstract	Campylobacter infection is one of the most common causes of bacterial gastroenteritis worldwide and a major global health threat due to the rapid development of antibiotic resistance. Currently, there are no vaccines approved to prevent campylobacteriosis, and rehydration is the main form of therapy. Secretory immunoglobulin A (SIgA) is the main antibody class found in mucous secretions, including human milk, and serves as the first line of defense for the gastrointestinal epithelium against enteric pathogens. In this study, we describe the prophylactic activity of orally delivered recombinant SIgA generated from two human monoclonal antibodies (CAA1 and CCG4) isolated for their reactivity against the flagellar-capping protein FliD, which is essential for bacteria motility and highly conserved across Campylobacter species associated with severe enteritis. In an immunocompetent weaned mouse model, a single oral administration of FliD-reactive SIgA CAA1 or CCG4 at 2 h before infection significantly enhances Campylobacter clearance at early stages post-infection, reducing the levels of inflammation markers associated with epithelial damage and polymorphonuclear (PMN) cells infiltration in the cecum lamina propria. Our data indicate that the prophylactic activity of CAA1 and CCG4 is not only dependent on the specificity to FliD but also on the use of the SIgA format, as the immunoglobulin G (IgG) versions of the same antibodies did not confer a comparable protective effect. Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01011
has license	cc-by
sha1sum (hex)	5a6f4ea102a3031e414fbd9c1398449ea17f5771
schema:url	https://doi.org/10.3389/fimmu.2020.01011
resource representing a document's title	Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA Against Campylobacter Infection
has PubMed Central identifier	PMC7296071
schema:publication	Front Immunol
resource representing a document's body	covid:5a6f4ea102a3031e414fbd9c1398449ea17f5771#body_text
is schema:about of	named entity 'enteritis' named entity 'campylobacteriosis' named entity 'highly conserved' named entity 'human milk' named entity 'Campylobacter' named entity 'human monoclonal antibodies' named entity 'oral administration' named entity 'vaccines' named entity 'cecum' named entity 'CAA1' named entity 'Campylobacter infection' named entity 'protein' named entity 'gastrointestinal epithelium' named entity 'immunoglobulin' named entity 'recombinant' named entity 'prophylactic' named entity 'Campylobacter infections' named entity 'SIgA' named entity 'Orally Administered' named entity 'exogenous' named entity 'carbohydrate' named entity 'm/z' named entity 'mice' named entity 'Sigma-Aldrich' named entity 'fluorescence' named entity 'forward scatter' named entity 'antibodies' named entity 'watery diarrhea' named entity 'cross-reactivity' named entity 'animal model' named entity 'Animal experiments' named entity 'infection' named entity 'binding activity' named entity 'bacterial gastroenteritis' named entity 'Tosoh' named entity 'prophylactic' named entity 'wild-type' named entity 'charge-coupled device' named entity 'enterocyte' named entity 'reducing agent' named entity 'paraformaldehyde' named entity 'SIgA' named entity 'recombinant' named entity 'infection' named entity 'mAb' named entity 'SIgA' named entity 'motility' named entity 'IgA' named entity 'virulence' named entity 'IgA' named entity 'size exclusion chromatography' named entity 'SIgA' named entity 'pathogenesis' named entity 'IL10' named entity 'Bio-Rad' named entity 'Molecular devices' named entity 'weaned'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software